ArticleLeukemia2023

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

J Hammersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.